FindTrial
Sign In

HLX43 DOSE 3

DRUG5 trials

Sponsors

Shanghai Henlius Biotech

Conditions

Carcinoma of Head and/or NeckCarcinoma, HepatocellularGastric or Gastroesophageal Junction AdenocarcinomaNasopharyngeal Carcinoma (NPC)Non Small Cell Lung CancerSolid Tumor Cancer

Phase 1

A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
RecruitingNCT06848699
Shanghai Henlius BiotechNon Small Cell Lung Cancer, Solid Tumor Cancer
Start: 2025-02-25End: 2027-10-01Target: 105Updated: 2025-11-17

Phase 2

A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy
RecruitingNCT06742892
Shanghai Henlius BiotechCarcinoma, Hepatocellular
Start: 2025-03-03End: 2027-06-05Target: 90Updated: 2025-03-10
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
RecruitingNCT06839066
Shanghai Henlius BiotechNasopharyngeal Carcinoma (NPC)
Start: 2025-04-02End: 2027-11-22Target: 70Updated: 2025-11-24
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RecruitingNCT06857279
Shanghai Henlius BiotechCarcinoma of Head and/or Neck
Start: 2025-04-22End: 2029-01-30Target: 167Updated: 2026-03-05
Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
RecruitingNCT07115485
Shanghai Henlius BiotechGastric or Gastroesophageal Junction Adenocarcinoma
Start: 2025-09-15End: 2028-09-30Target: 60Updated: 2025-11-18

Related Papers

Efficacy and safety of HLX43 (an anti–PD-L1 ADC) in previously treated recurrent/metastatic nasopharyngeal carcinoma: A multicenter, randomized phase 2 study.
Journal of Clinical Oncology2026-05-27